Proreo Pharma

2002: PROREO PHARMA founded by Günter Graubach and Rudolf Syz. Since then the company has quickly built-up a sizeable portfolio of interesting specialist products and has grown rapidly. 2003: Acquired the rights to Terlipressin (trademark: Haemopressin®) for the treatment of esophageal varices bleeding and hepatorenal syndrome from Curatis Pharma GmbH, Germany. 2003-2006: Further developed Terlipressin and significantly build-up the business. Today, Terlipressin is successfully registered and marketed in many countries in Europe and Asia as well as in Australia under the trademarks of Haemopressin®, Variquel® or Lucassin®. In the USA, the product is in late stage development. 2005: Incorporated Proreo Pharma SARL to register and market Haemopressin® and several other pharmaceutical products in France. 2006: Speciality European Pharma Ltd, a UK based pharmaceutical company financially backed by Advent Ventures acquired worldwide rights to Terlipressin by acquiring Proreo Pharma International AG, PROREO PHARMA's international business entity, as well as Proreo Pharma SARL, France. 2007: Established Proreo Pharma Innovation AG, Switzerland to develop and commercialise several products for rare and specialty care diseases. 2009: Proreo Pharma GmbH is set up to market and distribute pharmaceutical products in Germany. 2011: Established Ygraine Therapeutics Ltd, UK to develop a novel treatment for severe aura migraine and various other projects. 2012: Roland Rutschmann replaced Günter Graubach as Chief Executive Officer of PROREO PHARMA and became a shareholder of the company. Roland has a proven track record in pharmaceuticals for Rare Diseases and Specialty Care Diseases following his senior commercial management positions at Actelion and Orphan Europe. Günter now concentrates on the company's Corporate Development activities. 2013: Orphan Pharma Latin America S.A., Uruguay, is established to provide access to effective medicines for Latin American patients with rare medical conditions.